Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination with conventional and other novel agents for the treatment of multiple myeloma (MM). Although bortezomib is known to be a selective proteasome inhibitor, the downstream mechanisms of cytotoxicity and drug resistance are poorly understood. However, resistance to bortezomib as a single agent develops in the majority of patients, and activity in other malignancies has been less impressive. To elucidate mechanisms of bortezomib resistance, we compared differential gene expression profiles of bortezomib-resistant SUDHL-4 and bortezomib-sensitive SUDHL-6 diffuse large B-cell lymphoma lines in response to bortezomib. At concentrations that effectively inhibited proteasome activity, bortezomib induced apoptosis in SUDHL-6 cells, but not in SUDHL-4 cells. We showed that overexpression of activating transcription factor 3 (ATF3), ATF4, ATF5, c-Jun, JunD and caspase-3 is associated with sensitivity to bortezomib-induced apoptosis, whereas overexpression of heat shock protein (HSP)27, HSP70, HSP90 and T-cell factor 4 is associated with bortezomib resistance.

Original publication

DOI

10.1111/j.1365-2141.2006.06132.x

Type

Journal article

Journal

Br J Haematol

Publication Date

07/2006

Volume

134

Pages

145 - 156

Keywords

Antineoplastic Agents, Apoptosis, Boronic Acids, Bortezomib, Caspase 3, Caspases, Cell Proliferation, Cell Survival, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Gene Expression Profiling, Humans, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Polymerase Chain Reaction, Proteasome Inhibitors, Pyrazines, TCF Transcription Factors, Transcription Factor 7-Like 2 Protein, Tumor Cells, Cultured